Click here to go to the previous page
Biomarker Focused Strategies for Personalized Medicine
Program Code:
378
Date:
Wednesday, June 27, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
Renee Pridgen, Duke Clinical Research Institute, United States
PRESENTER
(S):
He is VP & Global Head, Cytometry Services for LabCorp Clinical Trials & received his PhD in immunology from Ohio State in 1977. He previously was Sr Princ. Sci. & Dir. of Core Flow Cytometry at Schering Plough, & Global Dir. of Oper. in Oncology/Cell Analysis for Esoterix Clinical Trial Services.
|
Deepak Voora, Duke Institute for Genome Sciences and Policy, United States
Dr. Litwack is an Amer. Assoc for the Advancement of Sci. Science & Tech. Policy Fellow in the Ofc of Biorepositories & Biospecimen Research at the National Cancer Institute, where he focuses on scientific & policy issues related to the use of human biospecimens in basic & translational research.
|
Description
Clinical care centers on standards based on epidemiological studies of large cohorts. However, these studies do not take into account genetic variability. This session discusses the pursuit of personalized medicine through biomarker collection.
Learning Objectives:
Describe the importance of incorporating biomarker collection into clinical trials in the pursuit of developing a more personalized approach to medicine and clinical care
Distinguish the "omics" of biomarkers (proteomics, genomics, transcriptomics, metabolomics).